PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7162583-1	1982	CDP-choline, an intermediate in the phospholipid metabolic pathway supposed to improve the functionality of the dopamine (DA) system, was administered to parkinsonian patients in a double-blind cross-over study versus placebo.	Dopamine	112-120	cut like homeobox 1	Homo sapiens	0-3	
7162583-1	1982	CDP-choline, an intermediate in the phospholipid metabolic pathway supposed to improve the functionality of the dopamine (DA) system, was administered to parkinsonian patients in a double-blind cross-over study versus placebo.	Dopamine	122-124	cut like homeobox 1	Homo sapiens	0-3	
7162583-7	1982	The positive effect of CDP-choline on parkinsonian patients already treated with L-dopa + dopa decarboxylase inhibitor stands for a possible action on the DA receptor through an activation of the phospholipid metabolism.	Levodopa	81-87	cut like homeobox 1	Homo sapiens	23-26	
7162583-7	1982	The positive effect of CDP-choline on parkinsonian patients already treated with L-dopa + dopa decarboxylase inhibitor stands for a possible action on the DA receptor through an activation of the phospholipid metabolism.	Dopamine	155-157	cut like homeobox 1	Homo sapiens	23-26	
7162583-7	1982	The positive effect of CDP-choline on parkinsonian patients already treated with L-dopa + dopa decarboxylase inhibitor stands for a possible action on the DA receptor through an activation of the phospholipid metabolism.	Dopamine	155-157	dopa decarboxylase	Homo sapiens	90-108